IBDEI2K4 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,43387,1,4,0)
 ;;=4^E10.630
 ;;^UTILITY(U,$J,358.3,43387,2)
 ;;=^5002619
 ;;^UTILITY(U,$J,358.3,43388,0)
 ;;=E10.641^^167^2078^87
 ;;^UTILITY(U,$J,358.3,43388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43388,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,43388,1,4,0)
 ;;=4^E10.641
 ;;^UTILITY(U,$J,358.3,43388,2)
 ;;=^5002621
 ;;^UTILITY(U,$J,358.3,43389,0)
 ;;=E10.649^^167^2078^88
 ;;^UTILITY(U,$J,358.3,43389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43389,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,43389,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,43389,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,43390,0)
 ;;=E10.65^^167^2078^86
 ;;^UTILITY(U,$J,358.3,43390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43390,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,43390,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,43390,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,43391,0)
 ;;=E11.40^^167^2078^95
 ;;^UTILITY(U,$J,358.3,43391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43391,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,43391,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,43391,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,43392,0)
 ;;=E11.42^^167^2078^98
 ;;^UTILITY(U,$J,358.3,43392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43392,1,3,0)
 ;;=3^DM Type 2 w/ DM Polyneuropathy
 ;;^UTILITY(U,$J,358.3,43392,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,43392,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,43393,0)
 ;;=E11.43^^167^2078^91
 ;;^UTILITY(U,$J,358.3,43393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43393,1,3,0)
 ;;=3^DM Type 2 w/ DM Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,43393,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,43393,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,43394,0)
 ;;=E11.49^^167^2078^93
 ;;^UTILITY(U,$J,358.3,43394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43394,1,3,0)
 ;;=3^DM Type 2 w/ DM Neurological Complications
 ;;^UTILITY(U,$J,358.3,43394,1,4,0)
 ;;=4^E11.49
 ;;^UTILITY(U,$J,358.3,43394,2)
 ;;=^5002649
 ;;^UTILITY(U,$J,358.3,43395,0)
 ;;=E11.51^^167^2078^96
 ;;^UTILITY(U,$J,358.3,43395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43395,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,43395,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,43395,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,43396,0)
 ;;=E11.52^^167^2078^97
 ;;^UTILITY(U,$J,358.3,43396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43396,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,43396,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,43396,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,43397,0)
 ;;=E11.610^^167^2078^94
 ;;^UTILITY(U,$J,358.3,43397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43397,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,43397,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,43397,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,43398,0)
 ;;=E11.620^^167^2078^92
 ;;^UTILITY(U,$J,358.3,43398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43398,1,3,0)
 ;;=3^DM Type 2 w/ DM Dermatitis
 ;;^UTILITY(U,$J,358.3,43398,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,43398,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,43399,0)
 ;;=E11.621^^167^2078^99
 ;;^UTILITY(U,$J,358.3,43399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43399,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,43399,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,43399,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,43400,0)
 ;;=E11.622^^167^2078^104
 ;;^UTILITY(U,$J,358.3,43400,1,0)
 ;;=^358.31IA^4^2
